Thermo Fisher Scientific (TMO) : Advisory Services Network scooped up 152 additional shares in Thermo Fisher Scientific during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 6,639 shares of Thermo Fisher Scientific which is valued at $974,937.Thermo Fisher Scientific makes up approximately 0.26% of Advisory Services Network’s portfolio.
Thermo Fisher Scientific opened for trading at $145.61 and hit $147.7521 on the upside on Wednesday, eventually ending the session at $147.14, with a gain of 1.05% or 1.53 points. The heightened volatility saw the trading volume jump to 14,97,750 shares. Company has a market cap of $58,306 M.
Other Hedge Funds, Including , Legacy Private Trust boosted its stake in TMO in the latest quarter, The investment management firm added 1,563 additional shares and now holds a total of 7,143 shares of Thermo Fisher Scientific which is valued at $1,048,950. Thermo Fisher Scientific makes up approx 0.16% of Legacy Private Trust’s portfolio.Premier Asset Managment reduced its stake in TMO by selling 1,195 shares or 1.36% in the most recent quarter. The Hedge Fund company now holds 86,640 shares of TMO which is valued at $12,723,084. Thermo Fisher Scientific makes up approx 3.23% of Premier Asset Managment’s portfolio.Alpha Windward reduced its stake in TMO by selling 31 shares or 2.01% in the most recent quarter. The Hedge Fund company now holds 1,514 shares of TMO which is valued at $220,045. Thermo Fisher Scientific makes up approx 0.16% of Alpha Windward’s portfolio. Oakbrook Investments sold out all of its stake in TMO during the most recent quarter. The investment firm sold 43,475 shares of TMO which is valued $6,318,657.Central Bank Trust Co boosted its stake in TMO in the latest quarter, The investment management firm added 73 additional shares and now holds a total of 233 shares of Thermo Fisher Scientific which is valued at $33,864. Thermo Fisher Scientific makes up approx 0.01% of Central Bank Trust Co’s portfolio.
On the company’s financial health, Thermo Fisher Scientific reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.11. The company had revenue of $4652.50 million for the quarter, compared to analysts expectations of $4551.79 million. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.
Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .Company shares were Reiterated by Topeka Capital Markets on Mar 2, 2016 to “Buy”, Firm has raised the Price Target to $ 155 from a previous price target of $145 .
Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.